7-hydroxymitragynine, commonly called 7-OH, is a kratom-associated alkaloid that has become increasingly visible in newer commercial product formats. While traditional kratom is generally associated with dried Mitragyna speciosa leaf, concentrated 7-OH products have appeared in tablets, gummies, liquids, and vaping formulations.

For researchers, understanding a 7-OH vape requires looking beyond the name on the packaging. The formulation, chemical composition, delivery method, and resulting aerosol can all influence how the product should be evaluated.

What Is 7-OH?

7-OH is a naturally occurring minor alkaloid in kratom. Natural kratom contains a range of alkaloids, with mitragynine generally being the predominant compound, while 7-OH occurs at much lower levels.

Commercial products marketed around concentrated 7-OH are different from ordinary botanical kratom because they can contain enhanced amounts of the specific compound. The FDA specifically distinguishes concentrated or added 7-OH products from the trace levels naturally present in kratom leaf.

7-OH has attracted scientific attention because of its activity at the mu-opioid receptor, making its concentration and formulation important subjects for toxicological and pharmacological research.

What Is a 7-OH Vape Formulation?

A vape formulation is a preparation designed to generate an aerosol when heated. Unlike a traditional kratom powder or oral tablet, the material is intended to enter the body through inhalation.

The exact composition of a 7-OH vape can vary considerably. Researchers may encounter products containing 7-OH alongside other kratom-related compounds, carrier ingredients, flavoring substances, or additional active ingredients.

A recent study examining 49 nonswallowed kratom-derived products found that 67% were vaping products. Most contained 7-OH, while some contained mitragynine extracts or mitragynine pseudoindoxyl. Several vaping products also contained intoxicating hemp cannabinoids.

This variability makes it difficult to characterize the entire category using a single formulation.

Key Component: 7-Hydroxymitragynine

The primary component of a product marketed as a 7-OH vape is, logically, the 7-OH itself. However, the stated amount on packaging should be treated as a product claim unless independently verified.

Recent analytical research found substantial differences between labeled and measured 7-OH quantities in some commercial products. Researchers also detected oxidation-related compounds and found evidence suggesting that many products labeled as 7-OH had a semisynthetic origin.

For research purposes, independently measuring the actual concentration is therefore important.

Other Kratom-Related Alkaloids

A formulation may contain compounds other than 7-OH.

Mitragynine is the principal alkaloid in natural kratom and may be present in some kratom-derived formulations.

Mitragynine pseudoindoxyl is another kratom-related compound that has appeared in newer commercial products. It is not naturally present in fresh kratom leaves in the same way as the plant's naturally occurring alkaloids and has become an important subject of regulatory and pharmacological discussion.

The presence of multiple active compounds can make it difficult to attribute an observed biological effect to 7-OH alone.

Carrier Ingredients and Formulation Materials

Vaping products generally require a liquid or other formulation system capable of producing an aerosol. Conventional electronic cigarettes commonly use ingredients such as propylene glycol, vegetable glycerin, flavorings, and other formulation components.

However, the exact ingredients used in products marketed as 7-OH vapes can vary, and researchers should not assume that every product uses the same carrier system.

This is particularly important when evaluating inhalation exposure because carrier materials and additives can contribute to the composition of the aerosol.

Flavoring and Other Additives

Some commercial kratom-derived vaping products contain flavors or scents intended to change the sensory characteristics of the product.

The 2026 study of nonswallowed kratom-derived products reported that most products contained flavoring or scent, and some used fruit or mint imagery, formulation colors, or other packaging features.

For researchers, these additives are relevant because an aerosol may contain more compounds than the primary active ingredient.

A complete formulation analysis should therefore identify both active and inactive ingredients whenever possible.

The Importance of the Aerosol

One of the most important distinctions between a liquid formulation and a vape product is that the material inhaled by the user is not necessarily identical to the material originally present in the liquid.

Heating can change chemical compounds and potentially produce degradation products. As a result, researchers studying 7-OH vaping should consider both the starting formulation and the resulting aerosol.

Relevant areas of investigation include:

• Chemical stability during heating

• Thermal degradation

• Aerosol composition

• Particle characteristics

• Potential respiratory exposure

• Differences between device temperatures

• Changes in chemical concentration during repeated use

These questions remain relatively under-studied for 7-OH-specific vaping products.

Why Testing the Finished Product Matters

Testing only the ingredients listed on a label may not provide a complete picture.

A research-oriented analysis can examine the original formulation for 7-OH, mitragynine, related alkaloids, additives, contaminants, and unexpected compounds. Researchers can then investigate the aerosol separately to determine whether heating changes the chemical profile.

This distinction is especially important because recent research has identified inconsistencies between labeled and measured concentrations in commercial 7-OH products.

A Certificate of Analysis can provide useful information about a particular batch, but it does not establish that a product is safe for inhalation.

Safety and Research Limitations

The available evidence concerning 7-OH vaping remains limited.

A 2026 study specifically examining nonswallowed kratom-derived products noted that there were no adequate clinical, safety, or pharmacokinetic data for products delivered through routes that bypass first-pass metabolism. The authors highlighted the need for additional research and regulatory attention.

The FDA currently recommends avoiding concentrated 7-OH products and states that they have not been proven safe or effective for any use. The agency has received reports involving addiction, withdrawal symptoms, anxiety, depression, gastrointestinal distress, insomnia, and seizures.

These findings do not establish the exact risk associated with every individual vape formulation, but they demonstrate why the category requires careful scientific evaluation.

Regulatory Context

The regulatory environment surrounding concentrated 7-OH is developing quickly.

In 2025, the FDA issued warning letters concerning companies marketing concentrated 7-OH products and stated that 7-OH is not lawful as a dietary supplement or conventional food ingredient.

In July 2026, the FDA reported that the DEA had begun a temporary scheduling process concerning 7-OH above a proposed threshold, along with certain synthetic 7-OH derivatives. Federal agencies stated that the action was directed toward concentrated and synthetic products rather than natural kratom leaf containing only trace naturally occurring 7-OH.

Researchers should therefore document the date and jurisdiction when discussing the regulatory status of a particular product.

What Researchers Should Look For

When analyzing a 7-OH vape formulation, several questions are particularly relevant:

1. What is the actual 7-OH concentration?

2. Are other kratom alkaloids present?

3. Are additional active compounds included?

4. What carrier and flavoring ingredients are used?

5. Does heating change the chemical composition?

6. Are degradation products generated?

7. Does the measured composition match the label?

8. Is the formulation consistent between batches?

Answering these questions provides a more useful chemical profile than relying on the product name alone.

Final Thoughts

7-OH vape formulations represent a relatively new area of kratom-related research. Their complexity comes from the combination of 7-hydroxymitragynine, other possible alkaloids, carrier materials, additives, device characteristics, and the chemical changes that may occur during heating.

Current evidence shows considerable variation among commercial products and significant gaps in human safety and pharmacokinetic research.

For researchers, the most useful approach is to evaluate the complete formulation rather than focusing exclusively on the advertised 7-OH concentration. Chemical analysis of both the original formulation and resulting aerosol can provide a more accurate understanding of what these products contain and how their composition may change during use.

As research and regulation continue to develop, 7-OH vaping should be treated as an emerging product category requiring independent analytical characterization and careful interpretation of the available evidence.